Literature DB >> 6956247

Susceptibilities of anaerobic bacteria to N-formimidoyl thienamycin (MK0787) and to other antibiotics.

T Kesado, K Watanabe, Y Asahi, M Isono, K Ueno.   

Abstract

The susceptibilities of 462 clinical anaerobic bacterial isolates to N-formimidoyl thienamycin and 16 other currently available and investigational antibiotics were determined by the agar dilution technique. N-Formimidoyl thienamycin was significantly more active than the reference antibiotics against most organisms tested, especially Bacteroides sp., including clindamycin-resistant strains. All 462 isolates were inhibited by 4 micrograms of N-formimidoyl thienamycin per ml, and no resistant strains were found in the species tested. N-Formimidoyl thienamycin was less active (i.e., had a higher 50% minimal inhibitory concentration) against Fusobacterium sp. than clindamycin, SM-1652, and piperacillin, and less active against Clostridium difficile than metronidazole, but was equally active or more active than the other reference antibiotics tested.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6956247      PMCID: PMC182066          DOI: 10.1128/AAC.21.6.1016

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp.

Authors:  W K Livingston; A M Elliott; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

2.  N-formimidoyl thienamycin (MK0787): in vitro study.

Authors:  S Shadomy; R S May
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

3.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

4.  In vitro activity of N-formimidoyl thienamycin (MK0787).

Authors:  F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

5.  In vitro activity of N-formimidoyl thienamycin (MK0787), a crystalline derivative of thienamycin.

Authors:  V W Horadam; J D Smilack; C L Montgomery; J Werringloer
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

6.  Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics.

Authors:  T Kesado; T Hashizume; Y Asahi
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

7.  In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

  7 in total
  18 in total

1.  Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis.

Authors:  T Ohkusa; I Okayasu; T Ogihara; K Morita; M Ogawa; N Sato
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

2.  Imipenem susceptibility testing with a commercially prepared dry-format microdilution tray.

Authors:  J L Staneck
Journal:  J Clin Microbiol       Date:  1986-06       Impact factor: 5.948

Review 3.  Anaerobic meningitis in children.

Authors:  A Tärnvik
Journal:  Eur J Clin Microbiol       Date:  1986-06       Impact factor: 3.267

Review 4.  In vitro activity of imipenem--a review.

Authors:  I Braveny
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

5.  In vitro activity of Sch 34343 and cefbuperazone against anaerobic bacteria.

Authors:  S D Shafran; J Wong; A W Chow
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

6.  Cefmenoxime therapy of serious bacterial infections.

Authors:  M E Gombert; L A Glasser; R H Eng
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

Review 7.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

8.  Comparative in vitro activities of cefpiramide and apalcillin against anaerobic bacteria.

Authors:  H Wexler; W T Carter; B Harris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

9.  Belgian Collaborative Study of the in-vitro susceptibility of the Bacteroides fragilis group. A Belgian Collaborative Study Group.

Authors: 
Journal:  Eur J Epidemiol       Date:  1988-09       Impact factor: 8.082

Review 10.  Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Ward; D M Richards
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.